AstraZeneca PLC(AZN)Earnings, Financials & Key RatiosAstraZeneca PLC (AZN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's forward P/E of 18.32 appears attractive given the sustained 12.5% revenue growth and the successful moderation of leverage to a 0.72 debt-to-equity ratio.
AstraZeneca PLC (AZN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
AstraZeneca PLC (AZN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $2.58vs $2.57+0.4% | $15.3Bvs $14.9B+2.4% |
| Q1 2026 | Feb 10, 2026 | $2.12vs $2.18-2.8% | $15.5Bvs $15.4B+0.4% |
| Q4 2025 | Nov 6, 2025 | $2.38vs $2.29+3.9% | $15.2Bvs $15.4B-1.5% |
| Q3 2025 | Jul 29, 2025 | $2.18vs $2.16+0.9% | $14.5Bvs $14.8B-2.1% |
Recent stock market news and headlines for AstraZeneca PLC (AZN)
On July 02, 2026, AstraZeneca PLC (AZN) shares rose 6.1% today to a current price of $195.15. The stock has performed well over the past year, showing a signifi
Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc (NYSE:AZN) to jointly develop a novel combination therapy for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer (NSCLC).
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese drugmaker said on Thursday.
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC).
Key metrics vs top competitors for AstraZeneca PLC (AZN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $193.12 | $299.39B | 29.53 | 8.63% | 17.46% | 22.89% | 1.68% | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — | |
| $57.97 | $118.36B | 16.80 | -0.22% | 15.01% | 38.96% | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — |
AstraZeneca PLC (AZN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AZN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AstraZeneca PLC (AZN) stock FAQ — growth, dividends, profitability & financials explained
AstraZeneca PLC (AZN) reported $60.44B in revenue for fiscal year 2025. This represents a 558% increase from $9.18B in 1996.
AstraZeneca PLC (AZN) grew revenue by 8.6% over the past year. This is steady growth.
Yes, AstraZeneca PLC (AZN) is profitable, generating $10.39B in net income for fiscal year 2025 (17.5% net margin).
Yes, AstraZeneca PLC (AZN) pays a dividend with a yield of 1.68%. This makes it attractive for income-focused investors.
AstraZeneca PLC (AZN) has a return on equity (ROE) of 22.9%. This is excellent, indicating efficient use of shareholder capital.
AstraZeneca PLC (AZN) generated $9.11B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
